Acute kidney injury and hepatorenal syndrome in cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 236-243

  Egerod Israelsen, Mads ^a   Gluud, Lise Lotte ^b   Krag, Aleksander ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Acute kidney injury; Acute on chronic liver failure; Adrenal insufficiency; Cirrhosis; Cirrhotic cardiomyopathy; Hepatorenal syndrome

Indexed keywords

ALBUMIN; TERLIPRESSIN; ALBUMINOID; LYPRESSIN;

ACUTE KIDNEY FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALCOHOL LIVER DISEASE; ASCITES; ASCITES FLUID; DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER HEMORRHAGE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UREMIA; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; CLASSIFICATION; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE COURSE; EARLY DIAGNOSIS;

ACUTE KIDNEY INJURY; ALBUMINS; ASCITES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYPRESSIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 84921466895     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12709     Document Type: Review

References (75)

1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 2013; 58: 593-608.
2. USBoD C. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310: 591-608.
3. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J. Hepatol. 2013; 59: 160-168.
4. Williams R, Horton R. Liver disease in the UK: a Lancet Commission. Lancet 2013; 382: 1537-1538.
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010; 53: 397-417.
6. Fede G, D'Amico G, Arvaniti V etal. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J. Hepatol. 2012; 56: 810-818.
7. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077.
8. Arroyo V, Gines P, Gerbes AL etal. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176.
9. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318.
10. Mehta RL, Kellum JA, Shah SV etal. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007; 11: R31.
11. Wong F, Nadim MK, Kellum JA etal. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709.
12. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin. Liver Dis. 2008; 28: 81-95.
13. Gines A, Escorsell A, Gines P etal. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236.
14. Salerno F, Guevara M, Bernardi M etal. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010; 30: 937-947.
15. Brinch K, Moller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J. Hepatol. 2003; 39: 24-31.
16. Gines P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med. 2009; 361: 1279-1290.
17. Moller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand. J. Gastroenterol. 2005; 40: 491-500.
18. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 2013; 60: 197-209.
19. Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective beta-blockers. Adv. Ther. 2013; 30: 659-670.
20. Ruiz-del-Arbol L, Urman J, Fernandez J etal. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218.
21. Ruiz-del-Arbol L, Monescillo A, Arocena C etal. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447.
22. Wong F. Cirrhotic cardiomyopathy. Hepatology International 2009; 3: 294-304.
23. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105-110.
24. Ruiz-Del-Arbol L, Achecar L, Serradilla R etal. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and a normal creatinine. Hepatology 2013; 58: 1732-1741.
25. Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med. Hypotheses 2012; 79: 53-55.
26. Triantos CK, Marzigie M, Fede G etal. Critical illness-related corticosteroid insufficiency in patients with cirrhosis and variceal bleeding. Clin. Gastroenterol. Hepatol. 2011; 9: 595-601.
27. Fede G, Spadaro L, Tomaselli T etal. Assessment of adrenocortical reserve in stable patients with cirrhosis. J. Hepatol. 2011; 54: 243-250.
28. Acevedo J, Fernandez J, Prado V etal. Relative adrenal insufficiency in decompensated cirrhosis. relationship to short-term risk of severe sepsis, hepatorenal syndrome and death. Hepatology 2013; 58: 1757-1765.
29. Theocharidou E, Krag A, Bendtsen F, Moller S, Burroughs AK. Cardiac dysfunction in cirrhosis-does adrenal function play a role? A hypothesis. Liver Int. 2012; 32: 1327-1332.
30. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 2003; 348: 727-734.
31. Fernandez J, Escorsell A, Zabalza M etal. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44: 1288-1295.
32. Arabi YM, Aljumah A, Dabbagh O etal. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010; 182: 1971-1977.
33. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002; 20: 252-261.
34. Olson JC, Wendon JA, Kramer DJ etal. Intensive care of the patient with cirrhosis. Hepatology 2011; 54: 1864-1872.
35. Moreau R, Jalan R, Gines P etal. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437.
36. Vincent JL, Moreno R, Takala J etal. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22: 707-710.
37. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am. J. Kidney Dis. 2003; 41: 269-278.
38. de Carvalho JR, Villela-Nogueira CA, Luiz RR etal. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J. Clin. Gastroenterol. 2012; 46: e21-26.
39. Scott RA, Austin AS, Kolhe NV, McIntyre CW, Selby NM. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol. 2013; 4: 191-197.
40. Fagundes C, Barreto R, Guevara M etal. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J. Hepatol. 2013; 59: 474-481.
41. Wong F, O'Leary JG, Reddy KR etal. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis with infection. Gastroenterology 2013; 145: 1280-1288.
42. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013; 62: 131-137.
43. Belcher JM, Garcia-Tsao G, Sanyal AJ etal. Association of AKI With mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762.
44. Ferreira CN, Rodrigues T, Cortez-Pinto H etal. The new definition of acute kidney injury in patients with cirrhosis: a critical look. Gut 2012; 61: 1513.
45. Altamirano J, Fagundes C, Dominguez M etal. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin. Gastroenterol. Hepatol. 2012; 10: 65-71. e3.
46. Piano S, Rosi S, Maresio G etal. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J. Hepatol. 2013; 59: 482-489.
47. Lopes JA, Melo MJ, Costa AC etal. Acute kidney injury and in-hospital mortality in critically ill patients with cirrhosis: a cohort study. Gut 2012; 61: 955-956.
48. Arroyo V. Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis? J. Hepatol. 2013; 59: 415-417.
49. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012; 61: 297-310.
50. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat. Rev. Gastroenterol. Hepatol. 2012; 9: 382-391.
51. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin. Gastroenterol. Hepatol. 2013; 11: 123-130. e1.
52. Fernandez J, Navasa M, Planas R etal. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
53. European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 2012; 57: 399-420.
54. Mathurin P, Louvet A, Duhamel A etal. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013; 310: 1033-1041.
55. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment. Pharmacol. Ther. 2013; 37: 845-854.
56. Thiele M, Del Giovane C, Askgaard G, Krag A. Pentoxifylline is superior to corticosteroids and n-acetylcysteine in alcoholic hepatitis: a multiple-treatment comparison meta-analysis. Hepatology 2013 2014; 58 (Suppl.): 581A.
57. Bendtsen F, Krag A, Moller S. Treatment of acute variceal bleeding. Dig. Liver Dis. 2008; 40: 328-336.
58. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 2010; 53: 762-768.
59. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938.
60. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-586.
61. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55: 1172-1181.
62. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233-243.
63. Krag A, Borup T, Moller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv. Ther. 2008; 25: 1105-1140.
64. Sort P, Navasa M, Arroyo V etal. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 1999; 341: 403-409.
65. Sanyal AJ, Boyer T, Garcia-Tsao G etal. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368.
66. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst. Rev. 2012; (9): CD005162.
67. Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179. author reply 1179-81.
68. Runyon BAAPGC. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology 2009; 49: 2087-2107.
69. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584.
70. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-834.
71. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59: 988-1000.
72. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871.
73. Boyer TD, Sanyal AJ, Garcia-Tsao G etal. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011; 17: 1328-1332.
74. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl. 2009; 15: 1142-1148.
75. Martin PD, Feng A, Brown S, Jr Fallon, M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144-1165.